Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, December 1st, 2022 1:00 - 5:00 PM

Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Bill Origer, MD; Mark Helm, MD; Cat Livingston, MD; Tim Langford, PharmD; Robin Moody, MPH; Russ Huffman, PMHNP; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Brandon Wells; Kyle Hamilton; Andrew Gibler, PharmD; Trevor Douglass, DC, MPH; Deborah Weston, JD; Jessica Ickes, MPA; Liz Stuart, MPH

Audience: Amy Burns, AllCare CCO; Brandie Feger, Advanced Health CCO; Georgette Dzwilewsk, Indivior; Janine Fournier, Jason Kniffin; Jim Slater, CareOregon; Kevin Gallagher, Fennec Pharmaceuticals; Lori McDermott, Viking HCS; Marc Rueckert, Argenx; Mark Kantor, AllCare CCO; Matt Metcalf, CSL Vifor; Melissa Snider, Gilead; Michael Foster, BMS; Norm Navarro, Providence Health Plan; Rick Frees, Vertex Pharmaceutical; Rochelle Yang, Teva; Saghi Maleki, Takeda Pharmaceuticals; Sydney Thomas, AllCare/APPE student; Tiffany Jones, Pacificsource; Tiina Andrews, UHA; Tom Telly, Supernus; Andrea Willcuts; Idorsia

---

I. CALL TO ORDER

A. Roll Call & Introductions
   - Called to order at approx. 1:05 p.m., introductions by Committee and staff
B. Conflict of Interest Declaration – no new conflicts of interest were declared
C. Approval of Agenda and October 2022 Minutes presented by Roger Citron
   ACTION: Motion to approve, 2nd, all in favor with one abstention
D. Department Update provided by Andrew Gibler, PharmD

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

E. Recognition of Dr. Helm provided by Trevor Douglass, DC

II. CONSENT AGENDA TOPICS

A. **Quarterly Utilization Report**
B. **Oncology Prior Authorization (PA) Updates**
Recommendation:
- Add: Lytgobi® (futibatinib); Tecvayli™ (teclistamab-cqyv); and Imjudo® (tremelimumab) to Table 1 in the Oncology Agents prior authorization (PA) criteria
C. **Orphan Drug Policy Updates**
Recommendation:
- Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Pedmark® (sodium thiosulfate) based on FDA-approved labeling
ACTION: Motion to approve, 2nd, all in favor

III. DUR ACTIVITIES

A. **ProDUR Report**: Lan Starkweather, PharmD
B. **RetroDUR Report**: Dave Engen, PharmD
C. **Oregon State Drug Review**: Kathy Sentena, PharmD
- **Asthma Guidance Update with a Focus on Changes for Managing Patients with Mild Asthma**
- **Population Trends in the Use of Migraine Preventative Treatments**

ACTION: Motion to approve, 2nd, all in favor

IV. DUR NEW BUSINESS

A. **Polypharmacy Drug Utilization Evaluation:** Dave Engen, PharmD
Recommendation:
- No policy changes are recommended
ACTION: Motion to approve, 2nd, all in favor

B. **Early Periodic Screening, Diagnostic and Treatment (EPSDT) Program PA Criteria Update:** Sara Fletcher, PharmD; Jessica Ickes, MPA; Liz Stuart, MPH
Recommendations:

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

- Update all PA criteria to support individualized review for members younger than 21 years of age who have an unfunded diagnosis, to evaluate whether medically appropriate and necessary
- In the absence of more specific criteria already approved by P&T, standard definitions for medically appropriate and necessary use will include:
  - FDA-approved or compendia-supported indication;
  - Trial and failure, contraindication, or intolerance to at least 2 preferred products (when available in the class);
  - and Documentation that the disease is of sufficient severity that it impact's the patient's health

ACTION: Motion to approve, 2nd, all in favor

V. DUR OLD BUSINESS

A. **Sedatives PA Criteria Update:** Sarah Servid, PharmD

Recommendations:

- Update PA criteria to limit sedative use to 30 days and encourage use of cognitive behavioral therapy for insomnia.

ACTION: The Committee recommended adding language regarding the member being unable to access such therapy and to explore options to auto-approve a short-term supply

Motion to approve, 2nd, all in favor

VI. PREFERRED DRUG LIST NEW BUSINESS

A. **Growth Hormone PA Criteria Update:** Dave Engen, PharmD

Recommendations:

- Update the growth hormone PA criteria to align with HERC coverage guidance and FDA-approved indications
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

B. **Drugs for Asthma/COPD Class Update:** Kathy Sentena, PharmD

Recommendations:

- No Preferred Drug List (PDL) changes recommended based on review of recently published evidence
- Update PA criteria to align with current guidelines

- Retire ICS/LABA specific criteria and subject non-preferred therapies to general PA criteria for non-preferred products
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

C. **Influenza Class Update:** Sara Fletcher, PharmD

Recommendations:

- No PDL changes recommended based on review of recently published evidence
- Update PA criteria with expanded indications and age ranges for peramivir and baloxavir
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

D. **Topical Products for Inflammatory Skin Conditions Class Update and New Drug Evaluations**: Deanna Moretz, PharmD

Recommendations:

- Update PA criteria to include use of ruxolitinib in patients 12 years and older, meeting HERC guidance for severe nonsegmental vitiligo, or having hand, foot, face, or mucous membrane involvement
- Designate roflumilast and tapinarof non-preferred on the PDL and subject to the PA criteria limiting use to:
    - Individuals meeting HERC guidance for severe plaque psoriasis or those having hand, foot, face, or mucous membrane involvement and,
    - FDA-approved ages and,
    - History of inadequate response to at least 2 moderate-to-high potency topical corticosteroids for at least 4 weeks
- Update PA criteria to remove PA for preferred products and accommodate individual review under EPSDT
- Combine the "Topical Anti-Psoriatic" class in with the "Topical Agents for Inflammatory Skin Conditions" class
- Evaluate costs in Executive Session

ACTION: Motion to approve, 2nd, all in favor

VII. EXECUTIVE SESSION

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

Members Present: Stacy Ramirez, PharmD; Bill Origer, MD; Mark Helm, MD; Tim Langford, PharmD; Robin Moody, MPH; Russ Huffman, PMHNP; Eddie Saito, PharmD

Staff Present: Sarah Servid, PharmD; Deanna Moretz, PharmD; Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Brandon Wells; Kyle Hamilton; Andrew Gibler, PharmD

VIII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Growth Hormone PA Criteria Update
Recommendation: Make Nutropin AQ® Nuspin non-preferred on the PDL
ACTION: Motion to approve, 2nd, all in favor

B. Drugs for Asthma/COPD Class Update
Recommendations: Make Combivent Respimat® non-preferred and Spiriva Respimat® preferred on the PDL
ACTION: Motion to approve, 2nd, all in favor

C. Influenza Class Update
Recommendations: Make no changes to the PDL
ACTION: Motion to approve, 2nd, all in favor

D. Topical Products for Inflammatory Skin Conditions Class Update and New Drug Evaluations
Recommendations: Make tazarotene gel non-preferred on the PDL
ACTION: Motion to approve, 2nd, all in favor

VIII. ADJOURN